CONSIDERATIONS TO KNOW ABOUT CANAGLIFLOZIN

There were no clinically significant dissimilarities from the pharmacokinetics of either midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when made use of concomitantly with finerenone. Many doses of 40 mg finerenone the moment-each day had no clinically suitable effect on AUC or Cmax with the BCRP and OATP substrate rosuvastatin.Othe